VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…
Treatment with EBT-107 led to a rapid reduction in clinical biomarkers and suppression of random HBV DNA integration with minimal…
LINKÖPING, Sweden and MISSISSAUGA, ON, May 15, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces…
DELRAY BEACH, Fla., May 14, 2025 /PRNewswire/ -- The global Radiation, Detection, Monitoring & Safety Market, valued at US$3,132.2million in 2023,…
SubtleHD delivers breakthrough efficiency and image quality to address Canada's urgent need for faster MRI access. MENLO PARK, Calif., May…
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud to announce The Dwayne Andrews Glioblastoma Research Grant…
- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - -…
New entity, ErnexaTX2, reflects progress toward clinical readinessCAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing…
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available…
Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still…